Skip to main content
Clinical Trials/NCT01677338
NCT01677338
Completed
Phase 2

A Multi-center, Open-label Comparison Study of a 13C-uracil Breath Test Versus 99mTechnetium Sulfur Colloid Gastric Emptying Scintigraphy to Evaluate Normal, and Delayed Gastric Emptying Time in Dyspeptic Subjects

Otsuka Pharmaceutical Co., Ltd.2 sites in 1 country20 target enrollmentStarted: July 2013Last updated:

Overview

Phase
Phase 2
Status
Completed
Enrollment
20
Locations
2
Primary Endpoint
Expired 13CO2 concentrations

Overview

Brief Summary

This study is a multi-center, open-label comparison study and aimed to evaluate the preliminary performance of this 13C-uracil GEBT to examine its abilities of identifying abnormal (delayed) gastric emptying rates in subjects.

Detailed Description

Approximately equal numbers of subjects will be enrolled in each of the 2 groups (with normal gastric emptying, and with delayed gastric emptying (gastroparesis)) to complete at least 10 subjects per group.

The subjects will first have their gastric emptying rates investigated by scintigraphy using the Solid Test Meal containing 500 uCi 99mTc sulfur colloid at Visit 1. Second, the subjects will have their gastric emptying rates investigated by scintigraphy and 13C-uracil GEBT simultaneously using the Semi solid Test Meal containing 500 uCi 99mTc sulfur colloid and 100 mg of 13C-uracil, respectively, at Visit 2. A comparison will be made between the results obtained at Visits 1 and 2 along with a comparison of the data obtained during Visit 2 for evaluation of the 13C-uracil GEBT.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
21 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Body mass index \[range is 18.0 to 33.0 kg/m2
  • Subjects with any upper GI symptoms
  • Stable creatinine

Exclusion Criteria

  • History of known peptic ulcers or stomach cancer.
  • History of stomach surgery or resection
  • History of significant hypersensitivity, intolerance, or allergy to any drug compound, food or other substance, unless approved by the investigator
  • History of alcoholism or drug abuse
  • History or presence of clinically significant GI, cardiovascular, central nervous system, hepatic, or renal disease; or other conditions
  • History of eating disorders
  • History or presence of an abnormal ECG, which, in the opinion of the investigator, is clinically significant

Arms & Interventions

13C-uracil and 99mTc sulfur colloid

Experimental

Subjects will consume the Semi-solid Test Meal containing 500 uCi 99mTc sulfur colloid and 100 mg of 13C-uracil.

Intervention: 13C-uracil (Drug)

13C-uracil and 99mTc sulfur colloid

Experimental

Subjects will consume the Semi-solid Test Meal containing 500 uCi 99mTc sulfur colloid and 100 mg of 13C-uracil.

Intervention: 99mTc sulfur colloid (Drug)

99mTc sulfur colloid

Experimental

Subjects will consume the Solid Test Meal containing 500 uCi 99mTc sulfur colloid.

Intervention: 99mTc sulfur colloid (Drug)

Outcomes

Primary Outcomes

Expired 13CO2 concentrations

Time Frame: 6 hours

Expired 13CO2 concentrations are obtained from breath test. The values will be calculated to Re(t)\[B\] semi-solid: remaining (%) of semi-solid test meal in stomach at t, t1/2\[B\] semi solid: half emptying time of semi-solid test meal , and tlag\[B\] semi-solid: lag time of semi-solid test meal.

Secondary Outcomes

  • Concentrations of 13C-uracil and its major metabolites in plasma and urine(6 hours)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials